Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
Hemato-Oncology Testing Market Size, Share & Trends Analysis Report 2025-2030 Featuring Key Players Roche, Abbott, EntroGen, Qiagen, and Cepheid (Danaher) Among Others
02.09.2025 12:59
Opportunities in the hemato-oncology testing market include rising lymphoma and myeloma cases, personalized therapy demand, and advanced molecular diagnostics. Emerging technologies like single-cell sequencing and long-read sequencing enhance diagnostic precision, thus driving market growth and improving patient outcomes. Hemato Oncology Testing Market Hemato Oncology Testing Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Hemato-Oncology Testing Market Size, Share & Trends Analysis 2025-
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
02.09.2025 08:15
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately. Dr. Phinney will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursues exciting new...
Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health?
26.08.2025 14:00
Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 4.2% over the past month. Since...
Abbott’s Esprit BTK System gains CE mark for PAD treatment
26.08.2025 09:13
The stent is engineered to keep arteries open, deliver everolimus for vessel healing, and gradually dissolve over time.
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
26.08.2025 06:29
Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of Abbott's denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.1,2,3
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
19.08.2025 13:00
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Taps Growing TMVR Market With Tendyne System
14.08.2025 12:33
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?
14.08.2025 11:00
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk
13.08.2025 13:21
The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic,
5 Must-Read Analyst Questions From Global Business Travel’s Q2 Earnings Call
13.08.2025 03:04
Global Business Travel’s second quarter results were met with a strong market reaction, as the company delivered revenue in line with Wall Street expectations despite flat year-on-year sales. Management attributed this outcome to a rebound in corporate travel demand in May and June after a weak April, as well as ongoing efficiency gains and cost controls. CEO Paul Abbott highlighted that the company’s focus on operating leverage and efficiency allowed for margin expansion, even as macroeconomic
Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting
08.08.2025 11:56
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board; A Long-Time Investor and Shareholder Engaged with the Company Since 2016 Gauzy Adopts Leaner Board to Reduce Corporate Expenses and Maintain Agility TEL AVIV, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in vision and light control technologies, today announced changes to its Board of Directors following the Company's annual general meeting
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
06.08.2025 20:05
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
06.08.2025 13:00
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
06.08.2025 11:41
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
Abbott Laboratories' (NYSE:ABT) Earnings Are Of Questionable Quality
06.08.2025 11:29
Investors were disappointed with Abbott Laboratories' ( NYSE:ABT ) earnings, despite the strong profit numbers. Our...
Medical Devices & Supplies - Diversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT)
06.08.2025 03:32
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including Abbott Laboratories (NYSE:ABT) and its peers.
QuidelOrtho Corporation (QDEL): A Bull Case Theory
04.08.2025 17:32
We came across a bullish thesis on QuidelOrtho Corporation on Valueinvestorsclub.com by Novana. In this article, we will summarize the bulls’ thesis on QDEL. QuidelOrtho Corporation’s share was trading at $27.39 as of July 25th. QDEL’s trailing and forward P/E were 9.16 and 11.22, respectively according to Yahoo Finance. QuidelOrtho (“Quidel”) represents a structurally growing diagnostics franchise […]
Abbott Laboratories (NYSE:ABT) Is Looking To Continue Growing Its Returns On Capital
04.08.2025 12:00
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...
AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue
31.07.2025 12:10
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT)
31.07.2025 11:00
Key Insights Abbott Laboratories' estimated fair value is US$133 based on 2 Stage Free Cash Flow to Equity With US$129...